KY 21
Alternative Names: Ionic compound KY21; KY-21Latest Information Update: 17 Mar 2023
At a glance
- Originator OLYS Pharma
- Class Analgesics
- Mechanism of Action Neurokinin 1 receptor antagonists; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Pain
Most Recent Events
- 16 Mar 2023 Preclinical trials in Pain in France (Topical) before March 2023 (OLYS Pharma website, March 2023)
- 16 Mar 2023 Pharmacodynamics data from a preclinical study in Pain released by OLYS Pharma (OLYS Pharma website, March 2023)
- 09 Jan 2023 OLYS Pharma has patent protection for bioactive synergistic multi-ionic complex in Belgium